Highlights
- Larimar shares gained 11.85% to USD 3.02 on November 13, with 2.53 mn shares traded.
- Nomlabofusp is an investigational protein replacement therapy designed to address frataxin deficiency, the underlying cause of Friedreich’s ataxia.
- Larimar described prior FDA alignment on components of its submission, including the agency’s willingness to consider skin frataxin as a potential novel surrogate endpoint.
- Larimar’s immediate priorities include regulatory engagement and continued FORWARD-FA enrollment.
A regulatory submission has moved a rare-disease treatment candidate into a new stage of review. Larimar Therapeutics Inc. (NASDAQ: LRMR) advanced 11.85% to USD 3.02 on 13 November 2026, days after announcing completion of its rolling Biologics License Application for nomlabofusp. The application seeks accelerated US approval for patients with Friedreich’s ataxia. Completion of a submission is a milestone, but it is not an approval decision and does not establish when or whether commercial sales might begin.
A Filing Focused on Frataxin Deficiency
Nomlabofusp is an investigational protein replacement therapy designed to address frataxin deficiency, the underlying cause of Friedreich’s ataxia. The company completed its rolling BLA submission to the US Food and Drug Administration on 9 November. The Accelerated Approval request draws on a regulatory pathway under which suitable evidence may support earlier review. The FDA has not been described as granting approval in the announcement, and the company continues to use conditional language concerning potential outcomes.
Clinical Evidence Behind the Application
Larimar described prior FDA alignment on components of its submission, including the agency’s willingness to consider skin frataxin as a potential novel surrogate endpoint. Previously disclosed open-label findings showed sustained increases in skin frataxin and directional improvements across several outcomes relative to a natural-history reference population. These are reported clinical observations, not evidence that the treatment has been approved. A surrogate endpoint requires assessment in the context of the regulatory review.
The Confirmatory Study Continues
The company is enrolling patients in FORWARD-FA, its global confirmatory Phase 3 trial. The double-blind, placebo-controlled study is designed to evaluate daily subcutaneous nomlabofusp over 18 months in ambulatory patients aged 2 to 40 who are new to treatment. Larimar expects approximately two-thirds of participants to be younger than 21. Enrollment and trial execution are future operational milestones, and the study’s outcome cannot be inferred from the completion of the BLA submission.
Submission, regulatory review and potential approval are different stages. Earlier open-label observations and the planned confirmatory Phase 3 study are also distinct sources of clinical information. The completed filing establishes that an application has been delivered, while any regulatory decision and future trial readouts remain subject to their own review and study processes.
Next Step Rests With Review and Research
Larimar’s immediate priorities include regulatory engagement and continued FORWARD-FA enrollment. The 9 November submission represents delivery of the application package, while the FDA’s subsequent review and any possible decision remain separate events. The company is developing an investigational therapy for a rare inherited disease, so clinical evidence and regulatory requirements remain essential considerations. Future disclosures can clarify application status, study progress and any additional steps requested by the agency.
For Larimar Therapeutics Inc., the dates attached to these disclosures are important. The closing price belongs to 13 November 2026, while the operating and financial figures relate to the periods stated by the company. A completed result, a current commitment and a management target each answer a different question. Keeping those distinctions clear allows the next corporate announcement to be compared with previously stated plans without assuming that a market move explains the underlying Business performance.
The stock closed at USD 3.02 on 13 November after a 11.85% daily rise. Its share Volume was 2.53 mn, and reported market Capitalization was USD 313.73 mn. Those market measures are dated observations; no causal claim about the company announcements is implied by their inclusion.






Please wait processing your request...